Assessment of CD40L and TSAB serum level in Graves disease patients

1. Introduction

Autoimmune disease is known as Graves’ disease. when the thyroid gland is the primary target. Additionally, It has the ability to. impact various more organs, such as the skin and eyes. This is the primary cause of hyperthyroidism [1]. It is present in individuals of all age groups, but is most prevalent in women who are of reproductive age. Graves’ hyperthyroidism arises from the existence of autoantibodies that target The TSHR refers to the receptor for thyroid-stimulating hormone. These autoantibodies act as stimulants, causing excessive synthesis of thyroid hormones. As a result, the thyroid gland becomes independent of pituitary regulation [2]. Result in the development of a diffuse goiter, and varying levels of hyperthyroidism. It has the ability to be linked to additional symptoms outside of the thyroid, such as thyroid eye disease (TED), dermopathy, or acropachy [3]. The primary treatment options use medications (like beta-blockers or antithyroid medications), radioiodine therapy (using iodine-131), and thyroidectomy [4]. Administration of antithyroid medications (ATD’s) can result in the cessation of the disease, Nevertheless a patient may experience a recurrence even after a prolonged period of remission. Both surgical and radioiodine ablation procedures result in hypothyroidism in nearly all patients. Up to 20 percent of patients may experience hypothyroidism as a result of medical treatment [5]. GD is influenced by genetic, epigenetic, and environmental factors [6].The clinical signs are linked to both hyperthyroidism and the autoimmune process. The excessive presence of thyroid hormones has a substantial impact on various body systems. As a result, indications and symptoms related to Graves’ disease can vary greatly and have a considerable impact on overall Life quality. Typical symptoms consist of tremors, intolerance to heat, weight loss despite regular eating, anxiety and irritability, Thyroid gland hyperplasia (goiter), and changes in menstrual cycles [7]. Cluster of differentiation (CD) CD40L, is a trimeric transmembrane protein belonging to the tumor necrosis family. It was initially discovered on immune system cells [8]. It attaches to CD40, a protein that is primarily found on antigen-presenting cells and B cells, although it can also be found on other cell types such thyroid follicular cells [9]. Following the attachment of cells, the CD40L that is present on the cell surface is subsequently broken down and/or released gradually over a span of minutes to hours, resulting in the formation of a soluble fragment known as sCD40L. This fragment maintains its whole biological functionality. It possesses several immunological activities, such as cell-to-cell contacts, antigen presentation, and pathogen capture [10]. The interaction between CD40 and sCD40L is increasingly identified as playing a significant role in the development of some autoimmune illnesses, including systemic lupus erythematosus, rheumatoid arthritis, and mixed connective tissue disease [11]. There is limited knowledge on the function of sCD40L in GD [12].Thyroid-stimulatory antibodies (TSAB), specifically (TRAB), are responsible for causing Graves’ disease (GD) in people who are suspected of having hyperthyroidism. These antibodies serve as a diagnostic biomarker for GD [13, 14]. TSAB which imitate the function of TSH by promoting the synthesis of two primary thyroid hormones, triiodothyronine (T3) and thyroxine (T4) [15].

2. Material and method

3. Results

Patients underwent diagnostic procedures including a thyroid ultrasound, a TSAB test, and assessments of thyroid function (TSH and TT4). The patient cohort comprised 13 males, accounting for 28.89% of the group, and 32 females, representing 71.11% of the group. The study included participants ranging in age from 8 to 80 years. Levels of CD40L was examined between Graves’ disease group and a group of control. The average value of Cd40L in the sick group was 453.54 ± 16.02, while the average value in the control group was 175.59 ± 4.14. The findings were highly significant in comparison to the research groups. ( P < 0.01 ), as listed at the Table 1.

3.1. CD40L as predictive diagnostic test for Graves disease OPEN IN VIEWER

Figure 1.

ROC Curve of graves diseases predicted by immunological parameter of CD40L among study’s sample (n = 90).

Among a 90-study sample, the cutoff point value of CD40L for detect patients with high risk of developing graves diseases was > 267.03 with sensitivity of 93.3%, specificity of 100%, positive predictive value of 100%, negative predictive value of 93.75%, and highly excellent area under the ROC curve (AUC) of 0.97 ( P ⩽ 0.0001 ) (Table 2) (Fig. 1).

OPEN IN VIEWER

Table 2

Predective value of CD40L for diagnosis of Graves disease among studys sample (n = 90).

Validity model
Parameter	Sensitivity (sn)	Specificity (sp)	Positive predictive value (ppv)	Negative predictive value(npv)	Accuracy	Area under the curve (AUC)	significancy (P-value)
CD40L	93.3	100	100	93.75	96.67	0.97	< 0.0001

Correlation between autoantibodyTSAB parameter and diaseas duration of graves disease among patients groups: In respect to the correlation between TSAB values and disease duration of graves disease, it was found that there is no statistically significant correlation identified between TSAB values and disease duration (P = 0.422) as in Table 3.

Correlation between autoantibodyTSAB parameter and TSH among patients groups:

OPEN IN VIEWER

Table 3

Estimate of correlation coefficient between duration with TSAB among patients group.

Parameter	Correlation coefficient-r with duration	p-value
TSAB	0.12	0.422

In respect to the correlation between TSAB values and TSH, it was found that there is no statistically significant correlation identified between TSAB values and TSH (P = 0.923). Furthermore statistically significant correlation identified between CD40L and TSH (P = 0.0174) as in Table 4.

OPEN IN VIEWER

Table 4

Estimate of correlation coefficient between TSH with TSAB and CD40L among patients group

Parameters	Correlation coefficient-r	p-value
TSH & TSAB	−0.02	0.923
TSH & CD40L	−0.35	0.0174

A thyroid-specific autoimmune condition called Graves’ disease (GD) is the main cause of hyperthyroidism, which is characterized by an enlarged and overactive thyroid gland and extra-thyroidal symptoms [16].The CD40-CD154 (CD40 ligand; CD40L) co-stimulatory pathway is crucial for T-cell–dependent humoral immune responses, the formation of human memory, and the functioning of antigen-presenting cells. The CD40-CD154 pathway is believed to have a important impact on the development of GD by stimulating the activation of self-reactive B-cells, the functioning of germinal centers inside the thyroid, and TSH-R-Ab antibodies creation [17, 18]. Cluster of differentiation refers to a classification system used to identify and characterize distinct types of cells in the immune system. CD40L, also known as 40 ligand, is a trimeric transmembrane protein belonging to the tumor necrosis family. It was initially discovered on immune system cells [19]. The present investigation has shown that the levels of sCD40L were markedly elevated in patients with GD in comparison to the control group (p = 0.0001). Mysliwiec et al found that levels of sCD40L were higher in adult patients with GD compared to control subjects, however the difference was not statistically significant [20]. Metwalley et al. observed elevated levels of soluble CD40L in children recently diagnosed with GD in comparison to healthy individuals. Experimental studies have demonstrated that elevated concentrations of sCD40L in vitro are linked to the release of adhesion molecules and monocyte chemoattractant protein-1, as well as impaired migration of endothelial cells and O2 generation in monocytes. These findings suggest that sCD40L plays a significant role in regulating autoimmune and inflammatory responses, which are likely to contribute to the development of GD [21]. Immune tolerance breakdown towards thyroid antigens leads to the development of autoreactive CD4+ helper T cells that target TSH-R. T cell receptors bind to major histocompatibility complex class II molecules on antigen-presenting cells, primarily B cells, where they recognize and interact with TSH-R peptides. After the contact, CD154 (CD40 ligand) is synthesized and presented on T cells. This CD154 then binds to CD40 on B cells, resulting in the activation of B cells. The CD40-CD154 costimulatory pathway is crucial for the T cell-dependent humoral immune response and has a significant impact on the development of Graves’ disease by stimulating the activation of self-reactive B cells, facilitating the function of germinal centers inside the thyroid, and boosting the creation of TSH-R-Ab antibodies [22]. Indicating that the CD40-CD40L pathway could potentially be a focus for innovative therapeutic approaches in the treatment of autoimmune disorders. This study found no statistically significant link between TSAB readings and disease duration (P = 0.422) in 45 GD patients treated with ATD. Santos et al. documented that TSAb, a subtype of thyrotropin receptor autoantibody, is present in patients with Graves’ disease. TSAb has the capability to attach to thyrotropin receptors and induce the growth and activity of thyroid cells. It has been discovered that levels of TSAb are more accurate in predicting relapse of GD after discontinuation of ATD compared to TRAbs. Assessing TSAb levels at consistent low ATD doses could be a valuable method for managing ATD in patients with Graves’ disease [23]. Kahaly et al documented the levels of serum TSAb are directly proportional to the severity of GD. Their augmentation throughout MMI treatment serves as an indicator of persistent disease activity, while TSAb levels proved to be a more accurate early predictor of illness advancement, remission, or response to treatment [24].

5. Conclusion

The serum level of CD40L was significantly elevated in patients with Graves disease compared to the control group. This suggests that CD40L could potentially serve as a useful diagnostic test for predicting the presence of Graves disease. There is no statistically significant link seen between TSAB levels and the duration of the condition.